Sector: Health Care
Director information for IRONWOOD PHARMA INC CLASS A (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alexander Denner, Ph.D. | Founding Partner and Chief Investment Officer | 56 | ["Founding partner and chief investment officer of Sarissa Capital Management LP since 2011","Senior managing director at Icahn Capital LP from 2006 to 2011","Portfolio manager at Viking Global Investors and Morgan Stanley Investment Management","Board member of Attralus, Inc.","Chair of the board of directors of The Medicines Company and Sarissa Capital Acquisition Corp.","Member of the board of directors of Biogen Inc.","B.S. in mechanical engineering from MIT","M.S. and M.Phil. in mechanical engineering from Yale University","Interdisciplinary Ph.D. from Yale University","Significant experience overseeing operations and research and development of healthcare companies","Extensive experience as an investor, particularly with respect to healthcare companies","Broad healthcare industry knowledge"] | ["Governance and Nominating Committee"] | 2026 |
| Catherine Moukheibir | Former Chief Executive Officer | 66 | ["Former CEO of MedDay Pharmaceuticals","Chair of the board of directors of MedDay","Senior advisor for finance at Innate Pharma SA","Chief financial officer for Movetis N.V.","Director of capital markets for Zeltia Group S.A.","Board member of MoonLake Immunotherapeutics AG","Chair of the board of directors of Synthon B.V.","Board member of Esteve Healthcare, S.L.","Board member of Noema Pharma AG","Board member of CMR Surgical","M.A. in economics and an M.B.A. from Yale University","Extensive leadership career in the biopharmaceutical industry","Background in international finance"] | ["Audit Committee"] | 2026 |
| Jay Shepard | Venture Partner at Catalys Pacific Fund, LP | 68 | ["Venture partner at Catalys Pacific Fund, LP since March 2021","Former president and chief executive officer of Aravive, Inc. from 2015 to 2020","Executive chairman of Versartis, Inc. from 2013 to 2015","Executive partner at Sofinnova Ventures from 2008 to 2015","President and chief executive officer of NextWave Pharmaceuticals, Inc. from 2010 to 2012","Interim president and chief executive officer of Relypsa from 2005 to 2007","Vice president of commercial operations at Telik","Oncology business unit head of ALZA Pharmaceuticals","Over 35 years of experience in the pharmaceutical, biotechnology and drug delivery arenas","Participated in or led over 16 product launches","Holds a B.S. in Business Administration from the University of Arizona","Deep expertise in the pharmaceutical industry and recognized public company CEO and senior executive"] | ["Audit Committee"] | 2026 |
| Julie McHugh | Chair | 61 | ["Former Chief Operating Officer, Endo Health Solutions, Inc.","CEO of Nora Therapeutics, Inc.","Company group chair for the worldwide virology business unit of Johnson & Johnson","President of Centocor, Inc.","Oversaw development and launches of several products, including Remicade®","Led marketing communications for gastrointestinal drug Prilosec® at Astra-Merck Inc.","Board member of Lantheus Holdings, Inc. and Xellia Pharmaceuticals ApS","Served on multiple boards including Aerie Pharmaceuticals, Inc., Trevena, Inc."] | ["Audit Committee","Governance and Nominating Committee"] | 2026 |
| Mark Currie, Ph.D. | Partner, Iaso Ventures, LP | 71 | ["Partner of Iaso Ventures, LP","Manager of Sandcastle Biostudio LLC","Former chair of scientific advisory board of Cyclerion Therapeutics, Inc.","Former president and chief scientific officer of Cyclerion","Former senior vice president and chief scientific officer at Ironwood","Directed cardiovascular and central nervous system disease research at Sepracor, Inc.","Built and led discovery pharmacology at Monsanto Company","Board member of Antag Therapeutics ApS and Sea Pharmaceuticals, LLC","Chair of scientific advisory boards of Coefficient Bio, Prudentia Sciences and Scaffold Therapeutics, Inc.","Earned B.S. in biology and Ph.D. in cell biology"] | ["Compensation and HR Committee"] | 2026 |
| Marla Kessler | Founder and Co-Chief Executive Officer, Acelyst Consulting, LLC | 56 | ["Founder and Co-Chief Executive Officer at Acelyst Consulting LLC","Chief marketing officer of Datavant, Inc.","Chief customer officer of Aetion, Inc.","Advisor to the chief executive officer of IQVIA Holdings Inc.","Senior vice president for strategy, marketing and communications for IQVIA","Vice president for global services marketing and knowledge management at IQVIA","Regional leader of the IMS Consulting Group in Europe","Location manager for the London IMS Consulting Group","Senior principal at IMS Consulting Group","Led several marketing efforts for Pfizer Inc.","Consulted for McKinsey & Company","B.S. in economics from Arizona State University","M.B.A. from the Fuqua School of Business at Duke University","Expertise in strategic marketing, evidence-based research and customer experience in the life science industry"] | ["Compensation and HR Committee"] | 2026 |
| Thomas McCourt | CEO | 68 | ["Chief Executive Officer since June 2021","Led the U.S. brand team for denosumab at Amgen Inc.","Directed the launch and growth of ZELNORM™ at Novartis AG","Part of the founding team at Astra-Merck Inc.","Board of directors member for Pliant Therapeutics, Inc.","Previously served on the board of directors of Acceleron Pharma Inc."] | ["audit","compensation"] | 2026 |
